Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA). - Trial NCT06229522
Access comprehensive clinical trial information for NCT06229522 through Pure Global AI's free database. This phase not specified trial is sponsored by Centro di Riferimento Oncologico - Aviano and is currently Recruiting. The study focuses on Ovarian Cancer. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Centro di Riferimento Oncologico - Aviano
Timeline & Enrollment
N/A
Nov 16, 2023
Dec 31, 2037
Primary Outcome
To assess if the drugs' sensibility tested in the 3D organoids derived from biopsies could predict the clinical response (PFS) to therapy regimen for each individual ovarian cancer patient.,To assess if the drugs' sensibility tested in the 3D organoids derived from ascites fluids could predict the clinical response (PFS) to therapy regimen for each individual ovarian cancer patient.,To assess if the drugs' sensibility tested in the 3D organoids derived from biopsies could predict the clinical response (PFI) to therapy regimen for each individual ovarian cancer patient.,To assess if the drugs' sensibility tested in the 3D organoids derived from ascites fluid could predict the clinical response (PFI) to therapy regimen for each individual ovarian cancer patient.
Summary
The association of clinical, pathogenesis and mutational profile of patients affected by
 ovarian cancer have improved the armamentarium of therapies available for medical doctors.
 One of most remarkable advancements is represented by the introduction of PARP inhibitors in
 the front-line setting of advanced ovarian carcinoma. It is necessary to continue with this
 effort and introduce novel approaches to improve the survival rate as well as predictive
 biomarkers to approved therapies. Given the absence of predictive biomarkers to standard
 therapy, patients derived organoid could be a promising platform to test clinically available
 drugs and/or promising new molecules to explore the tumor sensibility in an ex-vivo model.
 The aim of this study is to correlate treatment sensibility measured in tumor derived
 organoids to clinical sensibility seen in real world patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06229522
Non-Device Trial